Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05617664
Other study ID # treatment of primary nocturnal
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 23, 2022
Est. completion date October 2023

Study information

Verified date August 2023
Source Benha University
Contact hosam abu el-nasr, MD
Phone 01286296939
Email hosamabuelnasr@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Investigators will study the efficacy and safety of mirabegron25 in treatment of primary nocturnal enuresis in comparison to oral desmopressin 120 mcg and behavioral therapy


Description:

No doubt that nocturnal enuresis is one of the commonest types of urinary incontinence which affect children and always run in family . Nocturnal enuresis occurs at the age of 5 years with leakage of urine involuntarily during sleep for two times or more per week in three consecutive months not due to congenital or acquired cause. Nocturnal enuresis can be categorized into primary or secondary depending on occurrence of bed dryness for more than six months or not . Nocturnal enuresis affects 15% to 20 % of children at five years old mainly due to delay of bladder development and function more in male children with presence of family history in half of cases but 15% of children with enuresis recover spontaneously every year . limitation of fluid intake, urotherapy and bedwetting alarms are non-pharmacological treatments of nocturnal enuresis while the mostly used drugs for treatment of NE are tricyclic antidepressants(Imipramine®) an arginine vasopressin analog (Desmopressin®) and anticholinergic drugs . Enuresis alarms have pitfalls which disgust a lot of patients as skin irritation, sleep disturbances of other family members and failure to wake the child so that about 30% of patients stop its usage . Desmopressin is approved as a first-line drug therapy for nocturnal enuresis , but a lot of series declared that monotherapy with desmopressin has little efficacy in treating patients which have bladder storage dysfunction furthermore, high recurrence rate after treatment cessation . The International Children's Continence Society (ICCS) recommended combination therapy for treatment of primary nocturnal enuresis after failure of first line therapy with desmopressin or enuresis alarms . As regard anticholinergic drugs, oxybutynin was firstly prescribed then tolterodine with less side effects and lately solifenacin . Cognitive impairment as a neurological side effect was authenticated for oxybutynin and other side effects (e.g. headache, dry mouth, behavior change, flushed cheeks, constipation, and blurred vision) were unbearable to many children and impulsed them to stop treatment early . Mirabegron, a b3-adrenoceptor (b3-AR) agonist was the answer to the question about a drug that can relax detrusor muscle and increasing bladder capacity without the limitations of anti-cholinergic drugs. Mirabegron is the first b3-AR agonist to be prescribed clinically for OAB symptoms in adults and showed promising outcomes . while it is not licensed to be used in children with overactive bladder, some early reports declared its efficacy and tolerability in children . So investigators will study the efficacy and safety of mirabegron in treatment of primary nocturnal enuresis


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date October 2023
Est. primary completion date September 2023
Accepts healthy volunteers No
Gender All
Age group 5 Years to 15 Years
Eligibility Inclusion Criteria: - primary nocturnal enuresis, - negligible daytime wetting, - wet at least 4 times over 4 weeks - normal clinical examination with no neurological or urological cause for the enuresis Exclusion Criteria: - secondary enuresis, polysymptomatic - neurologic bladder, neurological disorders, - urinary incontinence disorders - previous anti NE drugs.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
desmopressin 120 mcg oral tablets
treatment for three months then will stop
Mirabegron 25 MG Oral Tablet, Extended Release
treatment for three months then will stop
Behavioral:
behavioral therapy alone
no medications will be given to the patient

Locations

Country Name City State
Egypt Benha University Hospitals Banha Qaliopia

Sponsors (1)

Lead Sponsor Collaborator
Benha University

Country where clinical trial is conducted

Egypt, 

References & Publications (7)

Bayne AP, Skoog SJ. Nocturnal enuresis: an approach to assessment and treatment. Pediatr Rev. 2014 Aug;35(8):327-34; quiz 335. doi: 10.1542/pir.35-8-327. — View Citation

Blais AS, Nadeau G, Moore K, Genois L, Bolduc S. Prospective Pilot Study of Mirabegron in Pediatric Patients with Overactive Bladder. Eur Urol. 2016 Jul;70(1):9-13. doi: 10.1016/j.eururo.2016.02.007. Epub 2016 Feb 11. — View Citation

Herschorn S, Barkin J, Castro-Diaz D, Frankel JM, Espuna-Pons M, Gousse AE, Stolzel M, Martin N, Gunther A, Van Kerrebroeck P. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety o — View Citation

Neveus T, Fonseca E, Franco I, Kawauchi A, Kovacevic L, Nieuwhof-Leppink A, Raes A, Tekgul S, Yang SS, Rittig S. Management and treatment of nocturnal enuresis-an updated standardization document from the International Children's Continence Society. J Ped — View Citation

Nitti VW, Rosenberg S, Mitcheson DH, He W, Fakhoury A, Martin NE. Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction. J Urol. 2013 Oct;190(4):1320-7. doi: 10.1016 — View Citation

Park JS, Lee YS, Lee CN, Kim SH, Kim SW, Han SW. Efficacy and safety of mirabegron, a beta3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol. 2019 Aug;37(8):1665-1670. — View Citation

Vande Walle J, Rittig S, Bauer S, Eggert P, Marschall-Kehrel D, Tekgul S; American Academy of Pediatrics; European Society for Paediatric Urology; European Society for Paediatric Nephrology; International Children's Continence Society. Practical consensus — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary nocturnal enuresis improvement rate decrease number of nights or absent nights the patient get wet four months
Secondary side effects of drugs used appearance of any side effect of desmopressin or mirabegron three months
See also
  Status Clinical Trial Phase
Completed NCT02600676 - Transcutaneous Electric Nerve Stimulation (TENS) in Children With Enuresis N/A
Completed NCT04191863 - Sleep Architecture in Valproate-induced Nocturnal Enuresis in Primary School and Preschool Children.
Recruiting NCT03199508 - Clinical Values of Voiding Diary for Diagnosis and Treatment for Monosymptomatic Enuresis in Children N/A
Enrolling by invitation NCT05710718 - PureWick™ France and U.S. At-Home Pilot Study N/A
Recruiting NCT06135311 - Optimal Pulse Width Used in Transcutaneous Electrical Nerve Stimulation for Treating Nocturnal Enuresis in Children N/A
Completed NCT03047720 - Scheduled Awakenings for the Treatment of Nocturnal Enuresis N/A
Completed NCT02328092 - A Double-blind Randomized Clinical Trial on the Efficacy of Magnetic Sacral Roots Stimulation for the Treatment of NE N/A
Completed NCT02068560 - The Effect of Gender on Antidiuresis - Evaluated by Graded Low Dose Desmopressin Infusion N/A
Withdrawn NCT02337413 - Urotherapy vs. Urotherapy With Constipation Treatment for Nocturnal Enuresis Phase 4
Completed NCT01368913 - MINRIN® Orally Disintegrating Tablet (Fast Dissolving Desmopressin) and Tablets in Treatment of Primary Nocturnal Enuresis N/A
Terminated NCT04420585 - Desmopressin for Bedwetting in Children With SCD Phase 4
Completed NCT02538302 - Minirin Versus Oxybutynin for Nocturnal Enuresis in Children Phase 3
Recruiting NCT04676139 - The Safety and Efficacy of Fluoxetine for Refractory Primary Mono-symptomatic Nocturnal Enuresis in Children Phase 3
Completed NCT03812094 - Basic Bladder Advice and Alarm Therapy in Nocturnal Enuresis N/A
Recruiting NCT03477812 - Sleep and Nocturnal Enuresis: Ambulatory Polysomnographic Study
Completed NCT02178826 - Nocturnal Enuresis and Rapid Maxillary Expansion N/A
Recruiting NCT01575678 - The Effect of Melatonin on Nocturnal Enuresis Phase 2
Completed NCT01078753 - Study With Two Different Doses of Desmopressin Orally Lyophilisate Tablet With Nocturnal Enuresis Phase 3
Recruiting NCT04313192 - TENS Treatment for Bedwetting N/A
Completed NCT05178641 - Overnight Pant Study for Children With Nocturnal Enuresis N/A